Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQ8X4A
|
|||
| Drug Name |
KB105
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Autosomal Recessive Ichthyosis [ICD-11: ED20] | Phase 2 | [1] | |
| Company |
Krystal Biotech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein-glutamine gamma-glutamyltransferase K (TGM1) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05735158) A Phase 2, Randomized, Placebo-controlled Study of Topical KB105, a Replication-defective, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI). U.S.National Institutes of Health. | |||
| REF 2 | Preclinical Evaluation of a Modified Herpes Simplex Virus Type 1 Vector Encoding Human TGM1 for the Treatment of Autosomal Recessive Congenital Ichthyosis. J Invest Dermatol. 2021 Apr;141(4):874-882.e6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.